The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

Produced using Dyadic’s proprietary high-yield fungal microbial expression platforms and Fermbox Bio’s scale-up and biomanufacturing capabilities, Recombinant DNase I (RNase-free) is currently ...

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and ...

THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...

Recombinant antibody technology has addressed many problems associated with hybridoma-based platforms, opening the door to a new class of biologics. Today, this technology continues to contribute to ...

Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic ...

Cytokines are small proteins that serve as the fundamental chemical messengers of the immune system. They also play a key cell signaling role in stem cell biology, relaying messages that direct stem ...

Novel Delivery System for High-Molecular-Weight Collagen Advances Anti-Aging Science at the Society of Cosmetic Chemists' Annual Meeting In recent years, recombinant collagen has become a key ...

LYON, France--(BUSINESS WIRE)--BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission ...

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...